<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>Local treatment and IFNs</italic>. Based on the observation that the host IFN response is delayed in CoV infections, with subsequent over-activation of neutrophils in the lung and vascular leakage (
 <xref rid="b54-ijmm-46-02-0489" ref-type="bibr">54</xref>), IFN-stimulating substances administered by inhalation showed efficacy against SARS and MERS 
 <italic>in vitro</italic> and 
 <italic>in vivo</italic>. Inhaled substances have the advantage of lower volume of distribution (ASL has a volume of 20-30 ml) and can act early in COV infection during the viral fusion process, inhibiting the binding of its S protein to the host receptor (
 <xref rid="b71-ijmm-46-02-0489" ref-type="bibr">71</xref>).
</p>
